SRS16-86 是一种新型的第三代 ferrostatin，是 ferroptosis 的抑制剂。 应用： SRS16-86 在体内比 Ferrostatin-1 对代谢和血浆更稳定。SRS16-86 可用于肾缺血再灌注损伤 (IRI) 和脊髓损伤 (SCI) 研究。 Information SRS16-86 SRS16-86, a novel third-generation ferrostatin, is an inhibitor of ferroptosis . In vitro SRS16-86 exhibits ferroptosis-inhibiting ability in vitro by FACS analysis of erastin-treated HT-1080 cells and in NIH 3T3 cells. In vivo SRS16-86 (a novel third-generation ferrostatin) is more stable, to metabolism and plasma, and more potent, compared with the first-in-class compound ferrostatin-1 (Fer-1) to suppress ferroptosis in vivo. Even in conditions with extraordinarily severe IRI, SRS16-86 exerts strong protection to an extent which has not previously allowed survival in any murine setting. Cell Research(from reference) Concentrations：1 μM Incubation Time：24 h, 40 h